NASDAQ:LIFE - aTyr Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.5731 +0.01 (+1.78 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$0.5731
Today's Range$0.5610 - $0.6075
52-Week Range$0.38 - $4.13
Volume165,302 shs
Average Volume344,635 shs
Market Capitalization$17.35 million
P/E Ratio-0.31
Dividend YieldN/A
Beta2.6
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.16 per share

Profitability

Net Income$-48,200,000.00

Miscellaneous

Employees65
Market Cap$17.35 million
OptionableOptionable

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings data on Tuesday, November, 13th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.06. View aTyr Pharma's Earnings History.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for aTyr Pharma.

What price target have analysts set for LIFE?

4 analysts have issued twelve-month price objectives for aTyr Pharma's shares. Their forecasts range from $0.75 to $1.80. On average, they expect aTyr Pharma's stock price to reach $1.1833 in the next twelve months. This suggests a possible upside of 106.5% from the stock's current price. View Analyst Price Targets for aTyr Pharma.

What is the consensus analysts' recommendation for aTyr Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.

Has aTyr Pharma been receiving favorable news coverage?

News stories about LIFE stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. aTyr Pharma earned a news impact score of 2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.

Who are some of aTyr Pharma's key competitors?

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
  • Dr. David J. King, Chief Scientific Officer (Age 60)
  • Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
  • Dr. Sanuj K. Ravindran, Bus. Advisor (Age 47)
  • Xiang-Lei Yang Ph.D., Founder

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $0.5731.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $17.35 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.

What is aTyr Pharma's official website?

The official website for aTyr Pharma is http://www.atyrpharma.com.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]


MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  393 (Vote Underperform)
Total Votes:  717
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel